Tag: Anti fibrotic

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a median survival of 2-5 years from diagnosis [1.5.7]. This raises a critical question for patients and clinicians: **Does pirfenidone reverse fibrosis**, or does it only slow the decline?

Fibrotic diseases, characterized by organ scarring, represent a significant health burden, with idiopathic pulmonary fibrosis (IPF) being a primary example [1.2.2]. As of 2025, the key question, 'What is the new anti-fibrotic drug?', points towards nerandomilast, a promising agent nearing potential FDA approval [1.2.1, 1.2.5].